Glutamatergic Medications Show Promise for Obsessive-Compulsive Disorders
Psychiatry > > General Psychiatry-- Treatments resulted in lower seriousness ratings, meta-analysis recommends
by Paul Smyth, MD January 2, 2025
Glutamatergic medications revealed pledge in dealing with obsessive-compulsive and associated conditions (OCRDs), particularly obsessive-compulsive condition (OCD), a methodical evaluation and meta-analysis revealed.
Throughout 27 trials, glutamatergic medications as monotherapy or contributed to selective serotonin reuptake inhibitors (SSRIs) revealed a big impact size in enhancing OCRD signs (Cohen d -0.80, 95% CI -1.13 to -0.47) when the interventi...